BIOMARKER DISCOVERY IN GLUCOCORTICOID RESISTANCE IN EAE

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 目前还没有治愈多发性硬化症（MS）的方法。 免疫抑制和 包括糖皮质激素（GC）的免疫调节治疗用于治疗急性 多发性硬化症发作和缓慢复发。 然而，没有足够的生物标志物显示， 治疗效果和/或治疗抗性的发展。 因此， 这个项目是确定生物标志物，以监测免疫调节治疗是否 是否有效和/或患者是否出现治疗耐药性。 我们将 糖皮质激素治疗实验性自身免疫病小鼠研究 脑脊髓炎（EAE）作为MS的普遍接受的模型。 蛋白质组学方法的研究，我们希望发现蛋白质（生物标志物）， 表明GC治疗何时有效，并进一步向我们提供以下信息 GC抗性的机制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Currently there is no cure for multiple sclerosis (MS). Immunosuppressive and immunomodulatory treatments including glucocorticoids (GC) are used to treat acute attacks of MS and slow relapses. However, no adequate biomarkers exist to show treatment efficacy and/or development of treatment resistance. Therefore, the goal of this project is to identify biomarkers to monitor whether immunomodulatory treatments in MS are effective and/or whether patients develop treatment resistance. We will study glucocorticoid (GC) treatment of mice with experimental autoimmune encephalomyelitis (EAE) as a generally accepted model of MS. Combining immunological studies with proteomics methods we expect to discover proteins (biomarkers) that indicate when the GC treatment is effective and furthermore provide us information on the mechanisms of GC resistance.